Structure Optimization of Natural Product Catalpol to Obtain Novel and Potent Analogs against Heart Failure
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.4c02591 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Hanfang Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Bioreactor Engineering, Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, Frontiers Science Ce…. Hauptthemen laut MEDLINE: Heart Failure, Iridoid Glucosides, Apoptosis, Biological Products. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 65 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Shanghai Municipal Education Commission, State Key Laboratory of Bioreactor Engineering.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Heart failure (HF) is a major global health threat, characterized by high morbidity and mortality. Targeting cardiac hypertrophy has been identified as a potential therapy for HF, with current treatments showing limited efficacy. Our research aims to address this limitation by exploring new structural classes of therapeutic agents. Starting from the natural product catalpol, we designed a series of novel catalpol analogs to break through the structural limitations of natural analogs, improve the anti-HF efficacy and metabolic properties. Among these, compound JZ19 exhibited remarkable efficacy in both myocardial cell injury assays and in an isoproterenol-induced murine HF model, outperforming catalpol. Our findings indicate that JZ19 potently reversed cardiac function by modulating the PI3K-AKT-GSK3β pathway, a key regulator of hypertrophy and apoptosis. Moreover, JZ19 showed favorable pharmacokinetic properties and safety. Overall, our results provide direct pharmacologic evidence supporting the further development of JZ19 as novel HF therapeutics by inhibiting cardiac hypertrophy and apoptosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Bioreactor Engineering, Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, Frontiers Science Center for Materiobiology and Dynamic Chemistry, Shanghai Key Laboratory…
- College of Pharmacy, Dali University, Dali 671000, China.
- Key Laboratory of Xinjiang Phytomedicine Resource and Utilization, Ministry of Education, School of Pharmacy, Shihezi University, Shihezi 832003, China.
- Key Laboratory of Tropical Biological Resources of Ministry of Education, College of Pharmacy, Hainan University, Haikou 570228, China.
ORCID-Profile: Jian Li
Förderung
- National Key Research and Development Program of China
- Shanghai Municipal Education Commission
- State Key Laboratory of Bioreactor Engineering
- Innovative Research Team of High-level Local University in Shanghai
- National Natural Science Foundation of China
- Shanghai Morning Light Program
- Shanghai Frontier Science Center of Optogenetic Techniques for Cell Metabolism
Zitieren
APA
Liu, H., Guo, X., Yang, J., Xia, C., Yao, Y., Li, X., Liu, X., Yang, J., Li, X., Xu, Y., Li, J., & Wang, M. (2025). Structure Optimization of Natural Product Catalpol to Obtain Novel and Potent Analogs against Heart Failure. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c02591
Vancouver
Liu H, Guo X, Yang J, Xia C, Yao Y, Li X, et al. Structure Optimization of Natural Product Catalpol to Obtain Novel and Potent Analogs against Heart Failure. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c02591
BibTeX
@article{Liu2025,
author = {Liu, Hanfang and Guo, Xiaobo and Yang, Jin and Xia, Conglong and Yao, Yue and Li, Xiao and Liu, Xiaoyang and Yang, Junqi and Li, Xiaokang and Xu, Yixiang and Li, Jian and Wang, Manjiong},
title = {Structure Optimization of Natural Product Catalpol to Obtain Novel and Potent Analogs against Heart Failure},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.4c02591}
}
EUVIMED